The impact of testosterone-lowering medication on recidivism in individuals convicted of sexual offenses

References

• Ahn J, Shim G, Lee J, Lee J, Lee T, Roh I. 2013. Preliminary study of effect of leuprolide acetat treatment on sexual fantasy of sex offenders. Korean J Leg Med. 37(3):139–144. doi: 10.7580/kjlm.2013.37.3.139.
   Google Scholar
• Briken P, Boetticher A, Krueger RB, Kismödi E, Reed GM. 2019. Current legal situation for patients with paraphilic disorders and implications of the ICD-11 for paraphilic disorders in Germany. J Sexual Med. 16(10):1615–1622. doi: 10.1016/j.jsxm.2019.07.011.
   PubMed Web of Science ®Google Scholar
• Briken P, Hill A, Berner W. 2003. Pharmacotherapy of paraphilia with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J Clin Psychiatry. 64:890–897. https://www.psychiatrist.com/jcp/depression/sexual-dysfunction/pharmacotherapy-paraphilias-long-acting-agonists-luteinizing/.
   PubMed Web of Science ®Google Scholar
• Briken P, Müller JL, Berner W, Bödeker R-H, Vollmann J, Kasperk C, Koller M. 2017. Vom Scheitern einer Studie in Maßregelvollzugskrankenhäusern. Klinische Prüfung zum additiven Effekt von Triptorelin auf die Wirksamkeit von Psychotherapie [Failure of a study in forensic psychiatric hospitals. Clinical trial to investigate the additive effect of triptorelin on the efficacy of psychotherapy]. Nervenarzt. 88(5):480–485. doi: 10.1007/s00115-017-0301-7.
   PubMed Web of Science ®Google Scholar
• Briken P, Turner D, Thibaut F, Bradford J, Cosyns P, Tozdan S. 2018. Validation of the Change or Stop Testosterone-Lowering Medication (COSTLow) Scale using Delphi method among clinical experts. J Sex Martial Ther. 24:1– 25. doi: 10.1080/0092623X.2018.1491910.
   Google Scholar
• Briken P, Turner D. 2021. Pharmacotherapy for patients with compulsive sexual behavior disorder (CSBD). In: Balon R, Briken P, editors. Compulsive sexual behavior disorder: understanding, assessment, and treatment. Washington, DC: American Psychiatric Association Publishing. Chap. 7. pp. 95–108.
   Google Scholar
• Champeaux-Depond C, Weller J, Froelich S, Sartor A. 2021. Cyproterone acetate and meningioma: a nationwide-wide population based study. J Neurooncol. 151(2):331–338. doi: 10.1007/s11060-020-03672-9.
   PubMed Web of Science ®Google Scholar
• Chan YH. 2004. Biostatistics 203. Survival analysis. Singapore Med J. 45(6):249–256.
   PubMedGoogle Scholar
• Colstrup H, Larsen ED, Mollerup S, Tarp H, Soelberg J, Rosthøj S. 2020. Long-term follow-up of 60 incarcerated male sexual offenders pharmacologically castrated with a combination of GnRH agonist and cyproterone acetate. J Forensic Psychiatry Psychol. 31(2):241–254. doi:10.1080/14789949.2020.1711957.
   Web of Science ®Google Scholar
• Cooper AJ. 1981. A placebo-controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Compr Psychiatry. 22(5):458–465. doi:10.1016/0010-440X(81)90034-1.
   PubMed Web of Science ®Google Scholar
• Eher R, Gnoth A, Birklbauer A, Pfäfflin F. 2007. Antiandrogene Medikation zur Senkung der Rückfälligkeit von Sexualstraftätern: ein kritischer Überblick [The effects of antiandrogenic medication on relapse rates of sex offenders: a review]. Recht & Psychiatrie. 25(3):103–111. Retrieved from https://psychiatrie-verlag.de/product/eher-r-gnoth-a-birklbauer-a-pfaefflin-f-antiandrogene-medikation-zur-senkung-der-rueckfaelligkeit-von-sexualstraftaetern-ein-kritischer-ueberblick-einzelartikel-aus-rp-3-2007/.
   Google Scholar
• Emory LE, Cole CM, Meyer WJ. III. 1992. The Texas experience with depo-Provera: 1980. J Offender Rehabil. 18(3–4):125–140. doi: 10.1300/J076v18n03_11.
   Google Scholar
• Fox J. 2002. Cox proportional-hazards regression for survival data. Appendix to An R and S-PLUS companion to applied regression. https://socialsciences.mcmaster.ca/jfox/Books/Companion-1E/appendix-cox-regression.pdf.
   Google Scholar
• Gallo A, Abracen J, Looman J, Jeglic E, Dickey R. 2019. The use of leuprolide acetat in the management of high-risk sex offenders. Sex Abuse. 31(8):930–951. doi: 10.1177/1079063218791176.
   PubMed Web of Science ®Google Scholar
• Hall GCN. 1995. Sexual offender recidivism revisited: a meta-analysis of recent treatment studies. J Consult Clin Psychol. 63(5):802–809. https://psycnet.apa.org/buy/1996-93501-001. doi: 10.1037/0022-006x.63.5.802.
   PubMed Web of Science ®Google Scholar
• Hanson RK, Bussière MT. 1998. Predicting relapse: a meta-analysis of sexual offender recidivism studies. J Consult Clin Psychol. 66(2):348–362. doi: 10.1037//0022-006x.66.2.348.
   PubMed Web of Science ®Google Scholar
• Hanson RK, Harris AJR, Scott T-L, Helmus LM. 2007. Assessing the risk of sexual offenders on community supervision (User Report No. 2007-05). Ottawa: Public Safety and Emergency Preparedness Canada.
   Google Scholar
• Hanson RK, Thornton D. 2000. Improving risk assessments for sex offenders: a comparison of three actuarial scales. Law Hum Behav. 24(1):119–136. doi: 10.1023/A:1005482921333.
   PubMed Web of Science ®Google Scholar
• Hare RD. 2003. Manual for the psychopathy checklist-revised. 2nd ed. Toronto: Multi Health Systems.
   Google Scholar
• Harris A, Phenix A, Thornton D, Hanson RK. 2003. STATIC-99: Coding rules revised–2003. Ottawa: Solicitor General.
   Google Scholar
• Harris AJR, Hanson RK. 2004. Sex offender recidivism: a simple question (User Report No. 2004-03). Ottawa: Public Safety and Emergency Preparedness Canada.
   Google Scholar
• Helmus LM, Thornton D, Hanson RK, Babchishin KM. 2012. Improving the pre- dictive accuracy of STATIC-99 and STATIC-2002 with older sex offenders: revised age weights. Sex Abuse. 24(1):64–101. doi: https://doi.org/10.1177/1079063211409951.
   PubMed Web of Science ®Google Scholar
• Hill A, Briken P, Kraus C, Strohm K, Berner W. 2003. Differential pharmacological treatment of paraphilias and sex offenders. Int J Offender Ther Comp Criminol. 47(4):407–421. https://journals.sagepub.com/doi/pdf/?casa_token=hzn85Q34vxYAAAAA:g74nXHSkEKS1oIPvGvaQ32OhqsSItZQaPZ8cV515-l0HIOSL5DRfOkUE7ghKExqViWpwe7X37frH. doi: 10.1177/0306624X03253847.
   PubMed Web of Science ®Google Scholar
• Jehle J-M, Albrecht H-J, Hohmann-Fricke S, Tetal C. 2013. Legalbewährung nach strafrechtlichen Sanktionen. Eine bundesweite Rückfalluntersuchung 2007 bis 2010 und 2004 bis 2010 [Legal probation after criminal penalties. A Nationwide Recidivism Survey 2007 to 2010 and 2004 to 2010]. Mönchengladbach: Forum Verlag Godesberg GmbH. https://www.bmj.de/SharedDocs/Archiv/Downloads/Legalbwaehrung_nach_strafrechtlichen_Sanktionen_2007_2010_u_2004_2010.pdf?__blob=publicationFile&v=3.
   Google Scholar
• Jordan K, Fromberger P, Laubinger H, Dechent P, Müller JL. 2014. Changed processing of visual sexual stimuli under GnRH-therapy – a single case study in pedophilia using eye tracking and fMRT. BMC Psychiatry. 14(1):142. doi: 10.1186/1471-244X-14-142.
   PubMed Web of Science ®Google Scholar
• Khan O, Ferriter M, Huband N, Powney MJ, Dennis JA, Duggan C. 2015. Pharmacological interventions for those who have sexually offended or are at risk of offending (review). Cochrane Database Syst Rev. (2); Art. No: CD0079789. doi: 10.1002/14651858.CD007989.
   Google Scholar
• Koo KC, Ahn JH, Hong SJ, Lee JW, Chung BH. 2014. Effects of chemical castration on sex offenders in relation to the kinetics of serum testosterone recovery: implications for dosing schedule. J Sex Med. 11(5):1316–1324. doi: 10.1111/jsm.12492.
   PubMed Web of Science ®Google Scholar
• Landgren V, Malki K, Bottai M, Arver S, Rahm C. 2020. Effect of gonadotropin-releasing hormone antagonist on risk of committing child sexual abuse in men with pedophilic disorder. A randomized clinical trial. JAMA Psychiatry. 77(9):897–905. doi: 10.1001/jamapsychiatry.2020.0440.
   PubMed Web of Science ®Google Scholar
• Laschet U, Laschet L. 1967. Antiandrogentherapie der pathologisch gesteigerten und abartigen Sexualität des Mannes [Antiandrogen therapy of pathologically increased and abnormal sexuality of man]. Klin Wochenschr. 45(6):324–325. doi: 10.1007/BF01747114.
   PubMedGoogle Scholar
• Maletzky BM, Tolan A, McFarland B. 2006. The Oregon depo-Provera program: a five-year follow-up. Sex Abuse. 18(3):303–316. doi: 10.1007/s11194-006-9021-4.
   PubMed Web of Science ®Google Scholar
• McGrath RJ, Lasher MP, Cumming GF. 2012. The Sex Offender Treatment Intervention and Progress Scale (SOTIPS) psychometric properties and incremental predictive validity with Static-99R. Sex Abuse. 24(5):431–458. doi: 10.1177/1079063211432474.
   PubMed Web of Science ®Google Scholar
• Moulier V, Fonteille V, Pélégrini-Issac M, Cordier B, Baron-Laforêt S, Boriasse E, Durand E, Stoléru S. 2012. A pilot study of the effects of Gonadotropin-Releasing Hormone Agonist therapy on brain activation pattern in a man with pedophilia. Int J Offender Ther Comp Criminol. 56(1):50–60. doi: 10.1177/0306624X10392191.
   PubMed Web of Science ®Google Scholar
• Phenix A, Helmus M, Hanson RK. 2016. STATIC-99R: evaluators’ Workbook–2016. Ottawa: Solicitor General.
   Google Scholar
• Rettenberger M, Briken P, Turner D, Eher R. 2015. Sexual offender recidivism among a population-based prison sample. Int J Offender Ther Comp Criminol. 59(4):424–444. doi: 10.1177/0306624X13516732.
   PubMed Web of Science ®Google Scholar
• Rettenberger M, Haubner-MacLean T, Eher R. 2013. The contribution of age to the Static-99 risk assessment in a population-based prison sample of sexual offenders. Crim Justice Behav. 40(12):1413–1433. doi: 10.1177/0093854813492518.
   Web of Science ®Google Scholar
• Rösler A, Witztum E. 1998. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med. 338(7):416–422. doi: 10.1056/NEJM199802123380702.
   PubMed Web of Science ®Google Scholar
• Rösler A, Witztum E. 2000. Pharmacotherapy of paraphilias in the next millennium. Behav Sci Law. 18(1):43–56. doi: 10.1002/(SICI)1099-0798(200001/02)18:1<43::AID-BSL376>3.0.CO;2-8.
   PubMed Web of Science ®Google Scholar
• Sauter * J, Stasch * J, Klemke K, Emmerling A, Voß T. 2018. Das Absetzen antiandrogener Medikation im ambulanten Setting. Fortsetzungsbericht über die Auslassversuche der Berliner Stichprobe [Discontinuing antiandrogenic treatment in a forensic outpatient setting. A follow-up report of withdrawal trials of a Berlin sample]. Forens Psychiatr Psychol Kriminol. 12(4):352–359. doi: 10.1007/s11757-018-0498-8.
   Google Scholar
• Sauter J, Turner D, Briken P, Rettenberger M. 2021. Testosterone-lowering medication and its association with recidivism risk in individuals convicted of sexual offenses. Sex Abuse. 33(4):475–500. doi: 10.1177/1079063220910723.
   PubMed Web of Science ®Google Scholar
• Schmucker M, Lösel F. 2015. The effects of sexual offender treatment on recidivism: an international meta-analysis of sound quality evaluations. J Exp Criminol. 11(4):597–630. doi: 10.1007/s11292-015-9241-z.
   Web of Science ®Google Scholar
• Schober JM, Kuhn PJ, Kovacs PG, Earle JH, Byrne PM, Fries RA. 2005. Leuprolide acetate suppresses pedophilic urges and arousability. Arch Sex Behav. 34(6):691–705. doi: 10.1007/s10508-005-7929-2.
   PubMed Web of Science ®Google Scholar
• Sewall LA, Olver ME. 2019. Psychopathy and treatment outcome: results from a sexual violence reduction program. Personal Disord. 10(1):59–69. doi: 10.1037/per0000297.
   PubMedGoogle Scholar
• Soothill KL. 2010. Sex offender recidivism. Crime Justice. 39(1):145–211. https://www.jstor.org/stable/. doi: 10.1086/652385.
   Google Scholar
• Thibaut F, Cosyns P, Fedoroff JP, Briken P, Goethals K, Bradford JMW. 2020. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. World J Biol Psychiatry. 21(6):412–490. doi: 10.1080/15622975.2020.1744723.
   PubMed Web of Science ®Google Scholar
• Turner D, Basdekis-Jozsa R, Briken P. 2013. Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions. J Sex Med. 10(2):570–578. doi: 10.1111/j.1743-6109.2012.02958.x.
   PubMed Web of Science ®Google Scholar
• Voß T, Klemke K, Schneider-Njepel V, Kröber H-L. 2016. Wenn ja, wie lange? – Dauer antiandrogener Behandlung von Sexualstraftätern mit paraphilen Störungen: klinische Erfahrungen aus Auslassversuchen in der forensischen Nachsorgepraxis [When yes, for how long? – Duration of antiandrogenic treatment of sexual offenders with paraphilic disorders]. Forens Psychiatr Psychol Kriminol. 10(1):21–31. doi: 10.1007/s11757-015-0346-z.
   Web of Science ®Google Scholar
• Ziegler A, Lange S, Bender R. 2007. Überlebenszeitanalyse: survival analysis: cox regression. Dtsch Med Wochenschr. 132(1):e42–e44. doi: 10.1055/s-2007-959039.
   PubMedGoogle Scholar